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Abstract
Leber congenital amaurosis (LCA) is a severe retinal dystrophy manifesting from early infancy as poor vision or
blindness. Loss-of-function mutations in GUCY2D cause LCA1 and are one of the most common causes of LCA,
accounting for 20% of all cases. Human GUCY2D and mouse Gucy2e genes encode guanylate cyclase-1 (GC1),
which is responsible for restoring the dark state in photoreceptors after light exposure. The Gucy2e–/– mouse
shows partially diminished rod function, but an absence of cone function before degeneration. Although the
cones appear morphologically normal, they exhibit mislocalization of proteins involved in phototransduction. In
this study we tested the efficacy of an rAAV2/8 vector containing the human rhodopsin kinase promoter and
the human GUCY2D gene. Following subretinal delivery of the vector in Gucy2e–/– mice, GC1 protein was
detected in the rod and cone outer segments, and in transduced areas of retina cone transducin was appro-
priately localized to cone outer segments. Moreover, we observed a dose-dependent restoration of rod and cone
function and an improvement in visual behavior of the treated mice. Most importantly, cone preservation was
observed in transduced areas up to 6 months post injection. To date, this is the most effective rescue of the
Gucy2e–/– mouse model of LCA and we propose that a vector, similar to the one used in this study, could be
suitable for use in a clinical trial of gene therapy for LCA1.
Introduction
Leber congenital amaurosis (LCA) is a genetically het-erogeneous autosomal recessive disorder causing severe
retinal degeneration (den Hollander et al., 2008). It is generally
diagnosed in early infancy and is characterized by poor vision
or blindness with nystagmus and dramatically reduced or
absent electroretinogram. LCA1 is caused by mutations in the
GUCY2D gene and is the most prevalent form of LCA, ac-
counting for up to 20% of all LCA cases (Hanein et al., 2004;
Hunt et al., 2010).
Human GUCY2D and mouse Gucy2e genes encode the
retinal guanylate cyclase-1 (GC1) protein, which is located in
disc membranes of photoreceptor outer segments. The role of
GC1 is to replenish cGMP levels after light exposure (re-
viewed in Koch et al., 2002). In the dark, cGMP levels are
sustained at a steady rate, keeping the cGMP-gated channels
open and maintaining partial depolarization of the cells by
allowing influx of the inward current. Exposure to light leads
to cGMP hydrolysis and channel closure, facilitating a sharp
decline in intracellular Ca2 + and hyperpolarization of the
cells. Under low Ca2 + concentrations, guanylate cyclase-
activating proteins (GCAPs) stimulate GC1 activity resulting
in cGMP synthesis, reopening of the channels, and dark state
restoration. Mutations that inactivate GC1 lead to inability to
produce cGMP, persistent closure of the cGMP-gated chan-
nels, and therefore a state equivalent to constant light ex-
posure (Larhammar et al., 2009; Hunt et al., 2010).
The phenotype of the Gucy2e–/– mouse differs from that of
patients with LCA1 regarding rod function. Patients with
LCA1 have no detectable rod function as measured by
electroretinography (ERG), whereas Gucy2e–/– mice exhibit
diminished, but persistent rod function. This results from
functional redundancy provided by the GC2 gene expressed
in mouse rods, although why this mechanism appears not to
be operating in humans is unclear (Baehr et al., 2007; Helten
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et al., 2007). In both mouse and human, cone function is ab-
sent from birth. Cone degeneration in the mouse is detectable
from 9 weeks of age and continues over the next 6 months
(Coleman et al., 2004). It has been shown that, despite poor
rod function, the retina of patients with LCA1 may still be
largely intact in patients ranging from 20 to 53 years of age
(Pasadhika et al., 2010). LCA1 may therefore be more ame-
nable to gene therapy than other forms of LCA in which
photoreceptor cell survival is compromised much earlier.
Gene therapy for LCA1 has previously been evaluated in
the GUCY1*B chicken (Williams et al., 2006) and Gucy2e–/–
mouse (Haire et al., 2006; Boye et al., 2010). The initial studies,
using a bovine GC1 transgene and either a lentiviral vector
(Williams et al., 2006) or rAAV2/5 vector (recombinant
adeno-associated virus type 2 [AAV2] vector pseudotyped
with AAV5 capsid) (Haire et al., 2006) resulted in short-term
improvement of retinal function in the GUCY1*B chicken,
but no improvement in the Gucy2e–/– mouse. The more recent
study, using rAAV2/5 and a mouse transgene, achieved
significant restoration of visual function in the Gucy2e–/–
mouse (Boye et al., 2010). In treated Gucy2e–/– eyes, cone-
mediated (photopic) b-wave amplitudes increased up to 45%
of wild-type levels, and cones were preserved for up to 3
months posttreatment. Furthermore, behavioral analyses
demonstrated improvement in visual acuity and contrast
sensitivity. No improvement in rod function was reported.
In this study, we assessed the long-term efficacy of
rAAV2/8-mediated transfer of a human GC1 transgene and
have achieved the most effective rescue of the Gucy2e–/–
mouse model of LCA to date.
Materials and Methods
Experimental animals
Gucy2e–/– animals were provided by D.L. Garbers (Dallas,
TX). The homozygous line was maintained on a mixed 129/
SvJ and C57BL/6J background. To determine whether any
improvements following gene therapy fell within the normal
range for wild-type animals, pure inbred C57BL6/J were
used as wild-type controls. All the experiments were ap-
proved by the University College London (London, UK)
Ethics Committee and were performed under U.K. Home
Office license. The procedures were conducted in accordance
with the Association for Research in Vision and Ophthal-
mology (Rockville, MD) Statement for the Use of Animals in
Ophthalmic and Vision Research.
Plasmid construction and production of rAAV2/8
Human GUCY2D and mouse Gucy2e cDNAs were cloned
into the pD10_hRK_GFP construct (Khani et al., 2007). Before
cDNA insertion, the gene encoding green fluorescent protein
(GFP) was removed and cDNA was inserted in between the
human rhodopsin kinase (hRK) promoter and the simian
virus 40 (SV40) polyadenylation site to form the following
constructs: pD10_hRK_hGUCY2D (total length, 8162 bp) and
pD10_hRK_mGucy2e (total length, 7979 bp). The constructs
were verified by sequencing.
Recombinant AAV2/8 was produced by a previously
described tripartite transfection method (Gao et al., 2002) into
293 cells. AAV8 packaging, helper, and pD10_hRK_hGU-
CY2D or pD10_hRK_mGucy2e plasmids were combined with
polyethylenimine (PEI; Polysciences, Eppelheim, Germany)
and left to form complexes for 10 min. The mixture was ad-
ded to HEK293 cells and left for 24 hr. The cells were har-
vested and concentrated 2 days after transfection, and lysed
using repeated freeze–thaw cycles to release the vector. The
HEK293 cell nucleic acid component was removed by Ben-
zonase (Sigma-Aldrich, Dorset, UK) treatment and virus
preparation was cleared of cellular debris by multiple cen-
trifugation steps, followed by previously described purifi-
cation by ion-exchange chromatography (Davidoff et al.,
2004). The virus preparation was concentrated in a Vivaspin
4 concentrator (10 kDa; Sartorius Stedim Biotech/Fisher Sci-
entific, Loughborough, UK), washed in phosphate-buffered
saline (PBS), and concentrated further to 100–150ll. Viral
particle titers were determined by dot-blot analysis of puri-
fied virus preparations and plasmid controls of known
concentrations.
Subretinal injections
Subretinal injections of viral vectors were performed on
postnatal day 10 (P10) in the right eyes of Gucy2e–/– mice.
Left eyes were left as untreated internal controls. Double
injections of 1.5 ll each were performed per eye, targeting
superior and inferior hemispheres of the retina. The tech-
nique used to deliver subretinal injections was previously
described (Tan et al., 2009).
Electroretinographic analysis
Electroretinograms (ERGs) were recorded from both eyes
of injected Gucy2e–/– mice and age-matched C57BL6/J wild-
type controls starting from 2 weeks post injection. ERGs
were subsequently recorded on a 2-weekly basis up to week
8, and then monthly up to 6 months post treatment when the
animals were sacrificed. Uninjected left eyes of treated ani-
mals were regarded as untreated controls. All animals were
dark adapted overnight before ERG recordings. The animals
were anesthetized with a single intraperitoneal injection of a
0.01-ml/g mixture of Domitor (1 mg/ml medetomidine hy-
drochloride), ketamine (100 mg/ml), and water at a ratio of
5:3:42 before recording. The pupils were dilated with a drop
of Minims Tropicamide 1% (Bausch & Lomb/Chauvin
Pharmaceuticals, Essex, UK). Midline subdermal ground and
mouth reference electrodes were first placed, followed by eye
electrodes that were allowed to lightly touch the corneas. A
drop of Viscotears 0.2% liquid gel (Dr. Robert Winzer
Pharma/OPD Laboratories, Watford, UK) was placed on top
of the electrodes to keep the corneas moistened during re-
cordings. ERGs were recorded with commercially available
equipment (Espion E2; Diagnosys, Lowell, MA). Bandpass
filter cutoff frequencies were 0.312 Hz (low-frequency cutoff )
and 1000 Hz (high-frequency cutoff ). Scotopic, rod-mediated
responses were obtained from dark-adapted animals at the
following increasing light intensities: 0.001, 0.01, 0.1, 1, 3, 5,
and 10 cd/m2. Ten responses per intensity were recorded
for the first three intensities with 10-sec dark adaptation
between each. Five responses were recorded for all the
subsequent steps with 30-sec dark adaptation between each.
Responses were averaged for each intensity. For the rod-
mediated b-wave responses amplitudes were analyzed at a
scotopic light intensity of 0.01 cd/m2.
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Photopic, cone-mediated responses were performed after
a 10-min light adaptation on a background light intensity of
20 cd, which was used as background intensity for the du-
ration of photopic recordings, flash and flicker. Recordings
were obtained at the following increasing light intensities:
0.1, 1, 3, 5, 10, and 20 cd/m2. Twenty-five responses were
averaged for each intensity, with a 60-sec light adaptation
interval between each step. For the cone-mediated b-wave
responses amplitudes were analyzed at a photopic light in-
tensity of 20 cd/m2.
Photopic flicker followed photopic flash recordings, and
consisted of 25 flashes per frequency at the following fre-
quencies: 0.5, 2, 5, 10, 15, and 30 Hz.
Optomotor testing
Contrast sensitivities and visual acuities of treated and
untreated eyes were measured by observing the optomotor
responses of mice to rotating sinusoidal gratings (Opto-
Motryª; CerebralMechanics, www.cerebralmechanics.com/
CerebralMechanics_Inc./OptoMotry.html). Mice reflexively
respond to rotating vertical gratings by moving their head in
the direction of grating rotation. The protocol used yields
independent measures of the acuities of right and left eyes,
based on the unequal sensitivities of the two eyes to pattern
rotation: right and left eyes are most sensitive to counter-
clockwise and clockwise rotations, respectively (Douglas et al.,
2005; Alexander et al., 2007). Gucy2e–/– mice were previously
described to have normal optomotor rod behavior (Boye et al.,
2010). Therefore, to exclude any rod input, mice were light
adapted for at least 30 min before testing. A double-blind two-
alternative forced choice procedure was employed, in which
the observer was blinded to both the direction of pattern ro-
tation and to which eye received treatment. Acuity was de-
fined as the highest spatial frequency (at 100% contrast)
yielding a threshold response, and contrast sensitivity was
defined as 100 divided by the lowest percent contrast yielding
a threshold response. For photopic acuity, the initial stimulus
was a 0.200 cycles/degree sinusoidal pattern with a fixed
100% contrast. For photopic contrast sensitivity measure-
ments, the initial pattern was presented at 100% contrast, with
a fixed spatial frequency of 0.128 cycles/degree. Visual acuity
and contrast sensitivity were measured under photopic con-
ditions (62 log cd m–2). Visual acuities and contrast sensitiv-
ities were measured for both eyes of each mouse at least four
times on independent days. Data for naive Gucy2e–/– mice are
presented alongside for comparison (animals 1 and 2).
Tissue preparation for immunohistochemistry
and crude membrane protein preparation
All animals treated with low-titer vector were taken for
immunohistochemistry. For immunohistochemistry per-
formed on dark-adapted eyes, the animals were dark adap-
ted overnight and sacrificed in the dark, with the red light
head torch as the only light source. For those eyes collected
in the light a cautery mark was placed on the superior limbus
to aid in orientation. The cornea was pierced and the eye
placed in 4% paraformaldehyde (PFA) at 4C overnight.
Corneas were removed and a small V-shaped mark was cut
out of the sclera, where the cautery mark was present. Lenses
were removed and eyecups placed in a 20% sucrose–PBS
solution until sunken. The eyecups were then embedded in
optimal cutting temperature (OCT) embedding medium
(Raymond A. Lamb/Thermo Fisher Scientific, East Sussex,
UK), and frozen in isopentane previously cooled in liquid ni-
trogen. Embedded eyes were kept at - 80C until sectioned.
For Western blotting, a crude membrane preparation was
used to extract protein from the snap-frozen retinas. Each
retina was placed in 100 ll of low-salt homogenization buffer
(10 mM morpholinepropanesulfonic acid [MOPS], 5 mM
mercaptoethanol in water, and protease inhibitors added).
Tissue was broken up by multiple passages through a 25-
gauge needle. Salt content was then raised to 0.25 M by
adding 5 M NaCl and the homogenate was centrifuged at
4C for 5 min at 900· g to remove large debris. The extract
was further centrifuged at 15,000· g for 30 min at 4C, after
which membrane pellets were resuspended in 50ll of the
low-salt homogenization buffer.
Immunohistochemistry
Immunofluorescence for GC1, cone arrestin, and a-trans-
ducin was performed on freshly cut, frozen retinal sections
(thickness, 18 lm). Slides were incubated in blocking buffer
(2% normal goat serum [Dako, Ely, UK], 1% bovine serum
albumin [BSA], 0.1% Triton X-100 in PBS) for 1 hr at room
temperature. Antibodies were diluted and added to their
respective slides at the following dilutions: polyclonal rabbit
anti-GC1, 1:1000 (GC1 antibody used for immunohisto-
chemistry was generously provided by A. Dizhoor, Salus
University, Elkins Park, PA); polyclonal rabbit anti-cone ar-
restin, 1:10,000 (Millipore, Watford, UK); and polyclonal
rabbit anti-cone a-transducin, 1:2000 (Santa Cruz Bio-
technology, Santa Cruz, CA), and left to incubate at 4C
overnight. Slides were thoroughly washed in PBS and the
following secondary antibodies were diluted in block solu-
tion and applied: for GC1 and cone arrestin, Alexa Fluor 488
goat anti-rabbit IgG conjugate was used (diluted 1:2500;
Molecular Probes, Paisley, UK), and for a-transducin Alexa
Fluor 594 donkey anti-rabbit IgG conjugate was used (di-
luted 1:1000; Molecular Probes). Slides were incubated with
secondary antibodies for 2 hr at room temperature, followed
by PBS washes. Hoechst (Sigma-Aldrich) nuclear counter-
stain was used diluted to 1 lg/ml in PBS. Slides were
mounted in fluorescent mounting medium (Fluormount;
Dako) and staining was analyzed by microscopy (Leica TCS
SPE confocal microscope; Leica, Mannheim, Germany).
Western blotting
Membrane protein extracts were quantified in a Bio-Rad
protein assay (Bio-Rad, Hemel Hempstead, UK). Equal
concentrations of each sample were left at 37C for 30 min
before 10 · sample buffer was added. The samples were then
loaded onto 6% polyacrylamide gels and, after gel electro-
phoresis, transferred to nitrocellulose membrane for Western
blotting. After blocking the membrane in block solution (5%
skimmed milk powder–1% bovine serum albumin [BSA;
Sigma-Aldrich]–0.05% Tween 20 in PBS) overnight at 4C,
goat polyclonal anti-GC1 antibody [diluted 1:250; ROS-GC1
(C-13), Santa Cruz Biotechnology] was added and left at
room temperature for 2 hr. Membrane was thoroughly wa-
shed in PBS–0.05% Tween 20 and incubated with a horse-
radish peroxidase (HRP)-conjugated rabbit anti-goat IgG
antibody (diluted 1:5000; Dako) in block solution for 1 hr at
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room temperature. After PBS–0.05% Tween 20 washes, sig-
nal was developed with Amersham enhanced chemilumi-
nescence (ECL) Plus Western blotting detection reagents (GE
Healthcare, Chalfont St Giles, UK). Subsequent to image
analysis, the membrane was stripped of antibodies, using
prewarmed stripping buffer (100 mM mercaptoethanol, 2%
sodium dodecyl sulfate [SDS], 62.5 mM Tris-HCl), and the
stripping procedure was verified by repeating the signal
detection process followed by thorough washes in PBS–
0.05% Tween 20. The membrane was reblocked with the
same blocking solution as described previously and mouse
monoclonal anti-Kv2.1 potassium channel protein antibody
(diluted 1:10,000; UC Davis/NIH NeuroMab facility, Davis,
CA) was added and left at 4C overnight. The next morning
the membrane was washed thoroughly in PBS–0.05% Tween
20 and incubated with an HRP-conjugated anti-mouse IgG
antibody diluted 1:10,000 in block solution for 1 hr at room
temperature. Signal detection was repeated as described
previously.
Real-time RT-PCR
RNA was extracted from retinas treated with the high-titer
vector at 5 months post injection. The numbers for all real-
time RT-PCR analyses were as follows: treated group, n = 6
eyes; untreated group, n = 5 eyes; C57BL/6J wild-type group,
n = 3 eyes. RNA was extracted with an RNeasy mini kit
(Qiagen, Crawley UK). Equal quantities and up to 1lg of
RNA were used as a template for cDNA manufacture for
each sample. cDNA was produced with a QuantiTect reverse
transcriptase kit (Qiagen). Real-time quantitative RT-PCR
(qRT-PCR) was performed with a commercial thermal cycler
(7900HT; Applied Biosciences, Foster City, CA). All reagents
were obtained from Roche Diagnostics (Burgess Hill, UK).
The technique was based on FAM-labeled hydrolysis probes
(Roche Diagnostics), and primers were designed for specific
probe-binding regions using the Roche Universal Probe Li-
brary. The primers used to detect endogenous mouse Gucy2e
were as follows: CATGGACCTCACCTTTGACC (forward)
and CTGTGCGTTCTCGGATCA (reverse) in combination
with Roche universal probe #67. To detect the introduced
human GUCY2D transcript the following primers were used:
CGGCTGCTTACACAGATGC (forward) and GTACTCGGG
CTCCACTGGT (reverse) in combination with Roche
universal probe #5. To measure cone arrestin levels, the fol-
lowing primers were used: TGTGTTTGTTCAGGAGTTCA
CA (forward) and AGGCCCTGCTTCTGACAGT (reverse) in
combination with Roche universal probe #71. Cycling con-
ditions for the endogenous mouse Gucy2e and cone arrestin
reactions were 40 cycles of 94C for 30 sec, 60C for 1 min;
and for the human GUCY2D transcript 40 cycles of 94C for
30 sec, 50C for 1 min. All reactions were performed in
duplicate or triplicate. Absolute mRNA amounts were cal-
culated on the basis of the standard curve of control DNA
sample dilutions of known concentration, which was in-
cluded for every PCR performed. Water control was also
included for every primer–probe combination.
Statistical analyses
To analyze qRT-PCR, optomotry, and cone quantification
data, one-way analysis of variance (ANOVA) was used with
Tukey’s multiple comparison post-tests. Two-way ANOVA
for repetitive measures with Bonferroni post-tests was used
to statistically evaluate ERG data. The Student t test was
used to evaluate cone arrestin as a marker of cone num-
bers. All statistical analyses were performed with GraphPad
Prism version 5.01 for Windows (GraphPad Software,
San Diego, CA).
Results
GC1 protein localization and levels in eyes
of Gucy2e–/– mice following subretinal injections
of AAV2/8 vector carrying a GUCY2D transgene
Human GUCY2D cDNA was cloned into the AAV2
plasmid backbone with an hRK promoter and SV40 poly-
adenylation site. We have previously shown that this rho-
dopsin kinase promoter mediates efficient transgene
expression in both rods and cones (Khani et al., 2007;
Pawlyk et al., 2010; Sun et al., 2010). The plasmid was
packaged with AAV8 capsids to generate a recombinant
AAV2/8 vector (rAAV2/8_hRK_hGUCY2D), using a tri-
partite transfection method in HEK293 cells, and purified by
ion-exchange chromatography (Gao et al., 2002). Gucy2e–/–
mice were treated with two injections of 1.5 ll of vector at
7 · 1011 vector genomes (VG)/ml (low titer) or 4 · 1012 VG/
ml (high titer).
GC1 is localized to outer segments of mouse photorecep-
tors (Fig. 1a). Following subretinal injections of rAAV2/
8_hRK_hGUCY2D in postnatal day 10 (P10) Gucy2e–/– mice,
abundant GC1 was detected exclusively in photoreceptor
outer segments for up to 6 months post treatment (latest time
point examined; Fig. 1b), whereas no GC1 staining was ob-
served in the untreated eyes (Fig. 1c). Western blot analysis
confirmed that the transgene product was of the correct size
at 120 kDa (Fig. 1d). We also examined, using real-time RT-
PCR, the levels of GUCY2D transcript produced in Gucy2e–/–
eyes 5 months after injection of high-titer rAAV2/
8_hRK_hGUCY2D (Fig. 2). Total RNA was extracted from six
treated retinas, as well as from the retinas of four untreated
mice and three C57BL/6J wild-type controls. The human
GUCY2D transcript levels in Gucy2e–/– eyes that had received
high-titer vector were on average 30-fold higher than en-
dogenous transcript levels in C57BL/6J wild-type retinas
( p< 0.01, one-way ANOVA). However, as the transgene
transcript lacks the natural 5¢ untranslated region (UTR), it
may not be translated with the same efficiency as the en-
dogenous mRNA. These results are consistent with our im-
munohistochemical staining (Fig. 1a–c), but not our Western
blot data (Fig. 1d), which suggests that Gucy2e–/– mice that
received either low- or high-titer vector have lower levels of
GC1 compared with wild-type C57BL6/J mice. The incon-
sistency between the immunohistochemistry, qPCR, and
immunoblot data might be explained by the use of two
different antibodies for Western blotting and immunohisto-
chemistry. However, it is not appropriate to use immuno-
blotting or immunohistochemistry as a way of comparing
the levels of GC1 in treated Gucy2e–/– mice and untreated
wild-type mice because the polyclonal antibodies used are
raised against human GC1 and so most likely bind the hu-
man transgene product more efficiently than endogenous
mouse GC1. It is therefore not possible to determine the
levels of transgene product relative to endogenous protein in
wild-type mice.
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Restored localization and increased levels
of cone a-transducin in treated retinas
To modulate the sensitivity of the photoresponse and also
to protect photoreceptors in bright light, key components of
the phototransduction cascade, including arrestin and the
G-protein transducin, translocate between photoreceptor
compartments in mouse rods and cones (Elias et al., 2004;
Lobanova et al., 2010). In dark-adapted rods, arrestin is dis-
persed throughout the cell and translocates to the outer
segments on exposure to light; the reverse is true for trans-
ducin. In cones, arrestin translocates in the same manner as
in rods (Elias et al., 2004). However, cone a-transducin
translocation is triggered only by high light intensities
and the cones need to be saturated and unresponsive for
a prolonged period of time (Lobanova et al., 2010). It has
been demonstrated previously that localization of cone
a-transducin is perturbed in Gucy2e–/– cone photoreceptors,
with a-transducin localized to the inner segments and syn-
aptic regions of cones (Coleman and Semple-Rowland, 2005).
Our results are consistent with these findings; we observed
weak and mislocalized cone a-transducin staining in un-
treated Gucy2e–/– eyes. In the treated eyes, however, immu-
nohistochemical staining revealed increased levels of cone
a-transducin, correctly localized to the cone outer segments
(Fig. 3a). It has also been reported previously that localization
of cone arrestin is perturbed in Gucy2e–/– cone photoreceptors
(Coleman and Semple-Rowland, 2005), and that cone arrestin
remains in the outer segments and synaptic terminals re-
gardless of light conditions. However, we did not observe a
major difference in cone arrestin staining in C57BL/6J wild-
type and untreated Gucy2e–/– mice (Fig. 3b). Although there
was faint immunostaining throughout Gucy2e–/– cones that
was not seen in wild-type cones, in light-adapted animals the
bulk of the signal, as in wild-type animals, was present in cone
outer segments and synaptic terminals. Furthermore, after
dark adaptation, arrestin translocated normally throughout
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FIG. 2. GUCY2D transcript levels in Gucy2e–/– eyes treated
with high-titer vector. Real-time RT-PCR analyses comparing
levels of GUCY2D transcript in high-titer vector-treated Gu-
cy2e–/– eyes with endogenous Gucy2e transcript in C57BL/6J
wild-type eyes and untreated Gucy2e–/– eyes. The levels of
introduced GUCY2D transcript in treated eyes are 30-fold
higher than those seen in C57BL/6J wild-type control eyes
( p < 0.01, one-way ANOVA). Transcript levels detected in
untreated controls are significantly lower than the levels of
GUCY2D transcript detected in treated Gucy2e–/– eyes
( p < 0.001, one-way ANOVA).
FIG. 1. Correct size and localization of guanylate cyclase-1
(GC1) protein in treated Gucy2e–/– eyes. GC1 immunofluores-
cence (green) was detected in the outer segments of photore-
ceptor cells in (a) wild-type eyes and (b)Gucy2e–/– eyes treated
with low-titer (LT) vector. (c) No staining was observed
in untreated Gucy2e–/– eyes. 4¢,6-Diamidino-2-phenylindole
(DAPI) nuclear counterstaining is shown in blue. (d) Western
blot showing 120-kDa GC1 protein in Gucy2e–/– eyes treated
with low-titer (LT) or high-titer (HT) vector and in C57BL/6J
wild-type controls, but not in Gucy2e–/– untreated eyes (UT).
Kv2.1 was used as a loading control. OS, outer segments; IS,
inner segments; ONL, outer nuclear layer. Scale bar: 25lm.
Color images available online at www.liebertonline.com/hum
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cone photoreceptor cells. The localization and translocation of
cone arrestin was not altered after administration of vector
(Fig. 3b).
Dose-dependent, long-term restoration
of photoreceptor function in Gucy2e–/– mice
The effect of treatment on photoreceptor function was
tested over a 6-month period by electroretinography (ERG).
ERGs were performed on treated and untreated Gucy2e–/–
mice and on age-matched C57BL/6J wild-type control ani-
mals. The average scotopic (rod-mediated) b-wave ampli-
tude of untreated Gucy2e–/– mice was approximately 35%
of that of C57BL/6J wild-type animals at all time points
examined. There was no significant difference in scotopic
b-wave amplitudes after injection of control rAAV2/
8_hRK_hrGFP or low-titer vector (data not shown). Scotopic
b-wave amplitudes in Gucy2e–/– mice treated with high-titer
vector were, over time, significantly higher than those of
untreated mice ( p= 0.0005, two-way ANOVA). The b-wave
amplitudes were restored to 65–100% of wild type (Fig. 4a
and b).
Restoration of cone function was achieved with both high-
and low-titer vector (Fig. 4c). After injection of low-titer
vector, cone-mediated b-wave amplitudes were on average
20% of that from wild-type mice and were significantly dif-
ferent from those of untreated Gucy2e–/– mice at all time
points examined ( p < 0.05, two-way ANOVA). In animals
treated with high-titer vector, cone-mediated b-wave am-
plitudes were improved even further—on average 65% of
wild type. Cone-mediated b-wave amplitudes from treated
animals were significantly greater than those from untreated
controls at each time point examined ( p< 0.001, two-way
ANOVA). The cone-mediated ERG after injection of control
rAAV2/8_hRK_hrGFP vector was not different from un-
treated controls (data not shown).
After subretinal injection of high-titer rAAV2/
8_hRK_mGucy2e (vector carrying the mouse Gucy2e trans-
gene) we observed an increase in scotopic and photopic b-
wave amplitudes that was not significantly different from
that achieved after administration of high-titer rAAV2/
8_hRK_hGUCY2D ( p > 0.05, two-way ANOVA; Fig. 5a and
b). This similarity in the efficacy of the two vectors probably
reflects the 87% homology between mouse and human GC1
proteins.
FIG. 3. Cone a-transducin levels and localization are re-
stored in Gucy2e–/– treated eyes. C57BL/6J wild-type, Gu-
cy2e–/– eyes treated with low-titer (LT) vector and untreated
(UT) retinas were stained with antibodies against cone a-
transducin (a, red) and cone arrestin (b, green). (a) Restored
cone a-transducin localization to the outer segments of cones
in the treated eyes, comparable to wild-type eyes. The im-
ages in the first three columns were taken using the same
microscope settings, whereas the images in the last column,
designated as Gucy2e–/– UT*, are identical to those in the
Gucy2e–/– UT column except that they were taken with a long
exposure and lighting levels were manipulated in Adobe
Photoshop 7.0 Elements to reveal the signal in the red
channel. The results indicate substantially reduced levels of
cone a-transducin in untreated Gucy2e–/– eyes, and restored
levels in treated eyes. (b) The two left-hand columns are
images of retinal sections of eyes harvested and processed
under normal light conditions and the right-hand columns
are images of those harvested and processed in the dark. In
the light, cone arrestin is localized in the cone outer segments
and synaptic regions of wild-type as well as treated and
untreated Gucy2e–/– eyes. In the dark, cone arrestin is local-
ized throughout the cone cells in wild-type eyes, and in
treated and untreated Gucy2e–/– eyes. DAPI nuclear coun-
terstain is shown in blue. Scale bars: 15lm. Color images
available online at www.liebertonline.com/hum
‰
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FIG. 4. Improvement in cone and rod function in treated Gucy2e–/– eyes. (a) Representative electroretinographic (ERG)
traces from C57BL/6J wild-type mice, Gucy2e–/– mice 6 months after treatment with high-titer (HT) or low-titer (LT) vector,
and untreated Gucy2e–/– (UT) mice. Rod-mediated b-wave responses of Gucy2e–/– animals treated with low-titer vector were
no different from those of untreated eyes, whereas responses of animals treated with high-titer vector were restored to an
average of 65% of wild-type amplitudes. Cone-mediated ERG of Gucy2e–/– animals treated with low-titer vector improved on
average to 20% of wild-type amplitudes, whereas the responses of animals treated with high-titer vector were restored to 65%
compared with wild-type eyes. (b) Over time, scotopic b-wave amplitudes in Gucy2e–/– mice treated with high-titer vector
were significantly higher than those in untreated mice ( p = 0.0005, two-way ANOVA). (c) Data from animals treated with
low-titer vector were significantly different from those of untreated and wild-type eyes at all time points examined ( p< 0.05,
two-way ANOVA). Cone-mediated ERG responses of eyes treated with high-titer vector were significantly higher than those
of untreated eyes at all time points ( p < 0.001, two-way ANOVA) and significantly lower than in wild-type eyes at all time
points ( p< 0.05, two-way ANOVA), except at 2 weeks post injection.
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Improvement in cone-mediated optomotor responses
in Gucy2e–/– mice after treatment
As reported previously (Boye et al., 2010), residual rod
function in Gucy2e–/– animals is sufficient for robust scotopic,
rod-mediated optomotor behavior that is equivalent to that in
wild-type animals (data not shown). To assess restoration of
cone-mediated behavioral responses, optomotor analysis was
performed under photopic conditions on Gucy2e–/– mice 4
months after the animals received subretinal injection of high-
titer vector in one eye. We observed a substantial improve-
ment in cone-mediated optokinetic head tracking behavior as
a result of treatment (Fig. 6). Cone-mediated visual acuity in
untreated Gucy2e–/– eyes was 0.102– 0.011 cycles/degree
( – SD, n = 10 eyes; Fig. 6a), whereas average visual acuity in
treated eyes was 0.386 – 0.064 cycles/degree ( p < 0.0001, one-
way ANOVA). The visual acuity of treated eyes was signifi-
cantly lower than that of C57BL/6J wild-type controls, which
had an acuity of 0.518– 0.033 cycles/degree ( p < 0.05, one-
way ANOVA). However, the Gucy2e–/– mice used for these
experiments were of a mixed C57BL6/Sv129 genetic back-
ground and the acuity of treated eyes falls within the normal
range for other strains of wild-type mice including a mixed
C57BL/6J/Sv129 strain (0.418 – 0.046 cycles/degree) (Alex-
ander et al., 2007; Haruta et al., 2009; Boye et al., 2010). Contrast
sensitivity of treated Gucy2e–/– eyes improved significantly
following treatment (1.0 – 0.0 vs. 5.0 – 2.8; p< 0.05, one-way
ANOVA) (Fig. 6b), although it remained significantly lower
than the mean contrast sensitivity of C57BL/6J wild-type
controls (29.3 – 5.2; p < 0.05, one-way ANOVA).
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FIG. 5. Comparison of photo-
receptor function restoration af-
ter transfer of human GUCY2D
and mouse Gucy2e transgenes.
(a) Consistent rod ERG im-
provement was observed in eyes
treated with both vectors
(mean – SD). No statistically
significant difference was ob-
served between the efficacy of
rescue using both vectors
( p= 0.587, two-way ANOVA).
(b) Cone-mediated ERG b-wave
responses of Gucy2e–/– eyes
treated with the mouse tran-
script did not differ from those
treated with the human tran-
script ( p= 0.9887, two-way AN-
OVA). Cone-mediated ERG
responses achieved with the
mouse transcript were approxi-
mately 62% of the response seen
in C57BL/6J wild-type eyes,
compared with 65% achieved
with the human transgene.
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Cone preservation in transduced areas of retinas
By using immunolabeling against cone a-transducin and
peanut agglutinin (PNA) lectin, Coleman and colleagues
have shown that cone degeneration in Gucy2e–/– mice starts
to be apparent from 9 weeks of age and is slowly progressive
(Coleman et al., 2004). Loss of cones is more pronounced in
the inferior retina, and by 6 months few cones are present in
this region, whereas nearly 50% of cones still remain in the
superior retina (Coleman et al., 2004). Because of these re-
gional differences we carried out two subretinal injections in
order to administer vector to both superior and inferior ret-
ina. Six months after administration of low-titer vector, we
analyzed serial sections of treated eyes, using antibodies
against cone a-transducin and GC1 and used age-matched
untreated eyes as controls. By staining adjacent sections of
the eye we were able to determine whether cone preservation
took place in the regions transduced by the vector (Fig. 7). At
6 months posttreatment, both GC1 (green) and cone a-
transducin (yellow) immunostaining were visible in superior
and inferior regions of the treated retina, (Fig. 7a, insets e and
g; and Fig. 7b, insets f and h). In the areas surrounding
transduced regions, where GC1 immunofluorescence was
undetectable (Fig. 7a, insets I and k), no cone a-transducin
staining was seen (Fig. 7b, insets j and l). In untreated Gu-
cy2e–/– eyes (Fig. 7c, insets m and o), only superior regions of
the retina contained cones expressing cone a-transducin (Fig.
7d, inset n). The staining in these regions was also consid-
erably weaker compared with that in treated retinas. Few
cones were detected in the inferior regions of untreated eyes
(Fig. 7d, inset p). Quantification of cones in whole eye sec-
tions of Gucy2e–/– eyes treated with low-titer vector and
stained with cone a-transducin revealed a significant overall
increase in cone numbers (20%) in treated compared with
untreated retinas ( p< 0.01, one-way ANOVA) (Fig. 7r).
By comparing the cone counts described previously with
real-time RT-PCR data, we found that there was no statisti-
cally significant difference in cone arrestin levels per cone cell
between C57BL/6J wild-type (26.6 – 3.9 molecules/cone) and
untreated Gucy2e–/– animals (19.9 – 5.2 molecules/cone,
p= 0.1, Student t test), suggesting that cone arrestin transcript
levels are a good indicator of cone numbers. This allowed us
to use the previously isolated mRNA samples from the
Gucy2e–/– eyes injected with high-titer vector to determine
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FIG. 6. Restoration of cone-mediated optomotor behavior in Gucy2e–/– treated eyes. Shown is the photopic visual acuity and
contrast sensitivity measurements in two untreated Gucy2e–/– mice (animals 1 and 2), and six mice treated with high-titer
vector (animals 3–8) 4 months post treatment. Results are presented for each animal and averaged per group in the right-
hand graphs. (a) Robust improvement in visual acuity was consistently observed in treated eyes ( p< 0.0001, one-way
ANOVA). (b) A significant improvement in contrast sensitivity was detected in treated eyes ( p< 0.05, one-way ANOVA).
OD, right eye; OS, left eye.
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FIG. 7. Cone preservation in the transduced areas of Gucy2e–/– treated eyes. Shown are adjoining retinal sections of Gucy2e–/–
eyes 6 months post treatment with low-titer vector (a and b) and untreated contralateral eyes (c and d) stained with antibodies
against GC1 (a and c, green) and cone a-transducin (b and d, yellow). (e–l) Insets are images of corresponding regions outlined in
(a) and (b). In the areas where GC1 staining is evident in the treated eyes (e and g) there is also expression of cone a-transducin (f
and h). In the untransduced areas, where there is no GC1 (i and k), there is no cone a-transducin staining (j and l). (m and n)
Images of the superior retina, and (o and p) of the inferior retina of the untreated eye (c and d). There is no GC1 staining in the
untreated eye (c). Weak cone a-transducin staining is evident in the superior untreated retina (n) with few cone cells present in the
inferior part of the retina (p). Scale bars: (a) 500lm; (e) 100lm. (r) Number of cone cells determined by cone a-transducin staining
in Gucy2e–/– eyes treated with low-titer vector, compared with untreated Gucy2e–/– eyes and C57BL/6J wild-type controls. The
cone number in treated eyes was 20% higher than in untreated eyes ( p< 0.001, one-way ANOVA). (s) Real-time RT-PCR quan-
tification of cone arrestin mRNA (CAR) in wild-type, Gucy2e–/– untreated eyes and eyes 5 months post treatment with high-titer
vector. The levels of cone arrestin are 1.3 times higher in treated eyes compared with untreated eyes ( p<0.0001, one-way ANOVA)
and have increased to 70% of the levels in wild-type eyes. Color images available online at www.liebertonline.com/hum
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whether cone preservation was present 6 months post
treatment. The levels of cone arrestin mRNA in Gucy2e–/–
eyes treated with high-titer vector were 1.3-fold higher than
the arrestin levels in untreated eyes ( p < 0.0001, one-way
ANOVA; Fig. 7s). Cone arrestin transcript levels in the
treated eyes were restored to 70% of the levels seen in
C57BL/6J controls ( p < 0.001, one-way ANOVA).
Discussion
Gene supplementation studies have been performed in a
number of animal models of retinal degeneration, with in-
creasingly encouraging results (Ali et al., 2000; Acland et al.,
2001; Pawlyk et al., 2005; Alexander et al., 2007; Tan et al.,
2009; Komaromy et al., 2010; Simons et al., 2011). Further-
more, clinical trials have demonstrated the safety and effi-
cacy of AAV2/2-mediated gene therapy for the treatment
of LCA2, which is caused by deficiency in RPE65 (Bain-
bridge et al., 2008; Hauswirth et al., 2008; Maguire et al.,
2008).
In this study we assessed the efficacy of an rAAV2/8
vector carrying a human GUCY2D transgene in the Gucy2e–/–
model of LCA1. It follows two previous studies in which
AAV2/5 vectors carrying either the bovine or mouse GC1
transgene were used to treat the Gucy2e–/– mouse (Haire
et al., 2006; Boye et al., 2010). Use of the bovine transgene did
not improve retinal function (Haire et al., 2006). Although use
of an rAAV2/5 vector carrying the mouse transgene resulted
in significant improvements in cone ERGs (photopic b-wave
amplitudes up to 45% of wild type), and also in cone-
mediated vision, no improvements were seen in rod ERGs
(Boye et al., 2010). Although cone preservation was demon-
strated, the assessments were made at 3 to 4 months of age,
at a time when cones are still plentiful in the superior regions
and degenerating in inferior retinas.
In this study we used an rAAV2/8 serotype as previously
we and other groups have demonstrated more efficient
transduction of photoreceptor cells as well as higher levels of
transgene expression after the use of this serotype compared
with AAV2/5 (Yang et al., 2002; Allocca et al., 2007; Natku-
narajah et al., 2008). After administration of the vector, we
achieved the most successful rescue of the Gucy2e–/– mouse
model to date. We demonstrated appropriate localization of
the GC1 transgene product to the outer segments of rods and
cones and increased levels and appropriate localization of
cone a-transducin. In addition to the restoration of cone ERG
function to near wild-type levels and a robust improvement
in cone-mediated visual function, we also demonstrated for
the first time a significant improvement in rod ERG function
and long-term preservation of cones.
A study of adult patients with LCA1 ranging in age from
20 to 53 years has reported preservation of retinal structures
despite markedly impaired visual acuity (Pasadhika et al.,
2010). This suggests that LCA1 is a fairly stationary condition
with minor structural deterioration with age, and that there
might be a relatively long opportunity for treatment com-
pared, for instance, with patients of a similar age with RPE65
mutations whose retinal structures are compromised to a
greater extent (Pasadhika et al., 2010). Thus vectors similar to
the one used in this study could be suitable for use in a
clinical trial and have the potential to be highly effective in
patients with LCA1.
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